NEW YORK (GenomeWeb) – CRISPR therapeutics firm Intellia Therapeutics on Thursday evening priced its previously announced initial public offering of six million shares of common stock at $18 per share. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the IPO price.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.